Multiple myeloma: Current and future management in the aging population

Area of Science:

• Geriatric Medicine
• Hematology
• Oncology

Background:

• Increasing global lifespan necessitates specialized care for elderly multiple myeloma (MM) patients.
• Current MM treatments and clinical trials often lack specific data for older populations, especially octogenarians.
• Chronological age alone is insufficient for assessing physiological decline in older adults.

Purpose of the Study:

• To highlight the need for validated frailty assessment tools in managing elderly multiple myeloma (MM) patients.
• To emphasize the importance of risk stratification for tailoring therapeutic strategies in this population.
• To advocate for personalized treatment approaches that consider both disease-specific and patient-specific factors.

Main Methods:

• Review of current clinical trial data and management strategies for elderly multiple myeloma (MM) patients.
• Discussion on the limitations of using age as a sole indicator of physiological status.
• Emphasis on the integration of validated frailty assessment tools into clinical practice and trial design.

Main Results:

• Elderly MM patients represent a heterogeneous group requiring individualized care.
• Frailty assessment tools are essential for accurate risk stratification in older MM patients.
• Tailored therapeutic approaches can optimize outcomes, including survival and quality of life.

Conclusions:

• Validated frailty assessment is critical for optimizing treatment strategies in elderly multiple myeloma (MM) patients.
• Personalized risk stratification enables the selection of appropriate therapies, balancing efficacy and toxicity.
• The ultimate goals of MM management in older adults are to prolong survival and maintain quality of life.